Company intelligence / Profile preview

Micrima

Bristol, United Kingdommicrima.com ↗

Ownership: Private
Employees: ~23
Development stage: Commercial

Overview

Micrima has developed a non-invasive radio frequency and AI-powered device to measure and analyze breast tissue properties—primarily targeting early detection of breast cancer by providing instant data on breast density. The system aims to improve diagnostic accuracy and enable personalized imaging strategies. The technology has been trialed in clinical settings but does not yet have CE mark approval; commercial launch preparations are ongoing.

No published pivotal clinical results yet; the company reports ongoing clinical trials.

Therapeutic areas: Oncology
Modalities: DeviceNon-pharmacological therapy (radio frequency-based breast tissue analysis device)
Industry: Medical Imaging

Partnerships

Supported by Innovate UKacademic collaboration with University of Bristol

Beyond the preview

Go deeper on Micrima.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Micrima.

Explore the full profile